Biperiden

CHEMBL1101 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
311.5 g/mol
LogP
4.3
Phase
4

An anticholinergic medication used to treat symptoms of Parkinson's disease and drug-induced movement disorders such as akathisia and dystonia. It reduces tremor, rigidity, and muscle spasms by blocking muscarinic receptors in the brain. Common side effects include dry mouth, constipation, and urinary retention.

Moleküler Ağırlık

311,5000 g/mol

LogP

4,30

TPSA

23,50 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2

InChI

InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2

Molecular Formula

C21H29NO

HBD / HBA

1 / 2

Döndürülebilir Bağlar

5

Ağır Atomlar

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An anticholinergic medication used to treat symptoms of Parkinson's disease and drug-induced movement disorders such as akathisia and dystonia. It reduces tremor, rigidity, and muscle spasms by blocking muscarinic receptors in the brain. Common side effects include dry mouth, constipation, and urinary retention.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Biperiden is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1101. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2381. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.